N-乙基-3-硝基苯胺 | 191217-62-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-3-硝基苯胺
• 英文名称: 3-Ethyl-5-nitroanaline
• 英文别名: 3-Ethyl-5-nitroaniline
• CAS: 191217-62-6
• 化学式: C₈H₁₀N₂O₂
• 分子量: 166.18
• InChiKey: MPJLLFMVCWQMRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted Pyrazalones
  申请人：Lee Wen-Cherng

  公开号：US20100056505A1

  公开（公告）日：2010-03-04

  The invention is related to compounds of formula (I) as antagonists of the TGFβ family type I receptors, Alk5 and/or AIk 4, compositions and methods of use. The compounds of formula (I) can be employed in the prevention and/or treatment of diseases such as fibrosis (e.g., renal fibrosis, pulmonary fibrosis, and hepatic fibrosis), progressive cancers, or other diseases for which reduction of TGFβ family signaling activity is desirable.

  该发明涉及式(I)的化合物作为TGFβ家族类型I受体Alk5和/或AIk 4的拮抗剂，以及使用的组合物和方法。式(I)的化合物可用于预防和/或治疗纤维化（如肾脏纤维化、肺部纤维化和肝脏纤维化）、进展性癌症或其他需要降低TGFβ家族信号活性的疾病。
• [EN] ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS<br/>[FR] QUINOXALINEDIONES CONDENSEES ET SUBSTITUEES PAR ALKYLE, AZIDO, ALCOXY ET FLUORO ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE LA GLYCINE
  申请人：ACEA PHARMACEUTICALS, INC.

  公开号：WO1995012417A1

  公开（公告）日：1995-05-11

  (EN) Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.(FR) L'invention concerne des procédés de traitement ou de prévention de baisses de l'activité neuronale associées aux ictus, à l'ischémie, aux traumatismes du système nerveux central, à l'hypoglycémie et aux opérations chirurgicales, ainsi que de traitement de maladies dégénératives du système nerveux, notamment la maladie d'Alzheimer, la sclérose latérale amyotrophique, la chorée de Huntington, et le mongolisme. L'invention concerne également le traitement ou la prévention des conséquences négatives de l'hyperactivité des acides aminés excitateurs, de même que le traitement de l'anxiété, des douleurs chroniques, des convulsions, et la manière d'induire l'anesthésie, par administration à un animal requérant ce type de traitement, d'une 1,4-dihydroquinoxaline-2,3-dione substituée par alkyle ou par azido ou de ses sels pharmaceutiquement acceptables, qui ont un pouvoir de fixation élevé sur le récepteur de la glycine.

  (中) 本发明涉及一种治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症等神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥和诱导麻醉的方法，通过向需要此类治疗的动物注射具有高度结合甘氨酸受体的烷基或偶氮基取代的1,4-二氢喹噁啉-2,3-二酮或其药学上可接受的盐。
• EP0732942A4
  申请人：——

  公开号：EP0732942A4

  公开（公告）日：2000-03-22
• ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS
  申请人：ACEA PHARMACEUTICALS, INC.

  公开号：EP0732942A1

  公开（公告）日：1996-09-25
• NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS
  申请人：Scherzer Roni

  公开号：US20110224184A1

  公开（公告）日：2011-09-15

  The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid.